82 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
. These include PG, a chronic inflammatory skin disorder for which we started a Phase III study with the first patient treated in November 2023, the treatment … , a chronic debilitating systemic inflammatory skin disease and ANCA-associated vasculitis, or AAV, a rare and life-threatening autoimmune disease.
We are also
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
Exhibit 99.1
InflaRx Hosts R&D Event Highlighting the Promise of INF904
Thought leaders in complement inhibition, chronic spontaneous urticaria … -clinical studies with INF904, including chronic toxicology studies, as part of its effort to enable longer-term dosing of INF904 in future clinical
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
and company introduction Current understanding of the C5a/C5aR1 biology Prof. Dr. med. Jörg Köhl The Role of C5aR in chronic spontaneous urticaria … vilobelimab C5a Inhibitor OTHER INF904 Oral C5aR Inhibitor chronic spontaneous urticaria Phase IIa “basket study” anticipated by YE 2024 Data anticipated
6-K
EX-99.2
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
of pyoderma gangrenosum
We are developing vilobelimab for the treatment of pyoderma gangrenosum, or PG. PG is a rare, chronic inflammatory form … for more chronic inflammatory diseases. To expand the breadth of our anti-C5a/C5aR technologies, we are also developing INF904, an oral, small molecule
6-K
EX-99.3
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
:00 to 2:00 PM EDT – highlighting company plans for INF904 and the opportunity, the role of C5aR in chronic spontaneous urticaria (CSU … , including chronic toxicology studies, to enable longer-term dosing of INF904.
CSU and HS are two chronic inflammatory skin conditions in which C5a has
6-K
EX-99.1
sv8d84n5xd3l
21 Mar 24
Corporate Presentation March 2024
5:00pm
6-K
EX-99.1
uvlyscy2w6i5 w6nwf4
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
EX-99.1
t4xjxj517g50j jy
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
16t8cthxtlyyd
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
hxntjg7tjnqb i2j6s
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.3
j2bexlyo
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.1
6p9t2woi887 m9tmrk
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am
6-K
EX-99.2
1a9 efnjyvn649v87vmt
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.3
ostm5z3bjcdymfuoxy84
10 Aug 23
Report of Foreign Private Issuer
8:00am
424B5
vi2m0 6uvx
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
59nlcf471y93 fmnh0q
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
r9lnu
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
6-K
EX-99.3
3s8pgar8mahuhynfl
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.2
fnp lopnsse
11 May 23
Current report (foreign)
8:00am